Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:patches
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemical_formula |
C14 H19 NO2
|
| gptkbp:class |
gptkb:pharmaceuticals
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
gptkb:Ophthalmology
heart problems history of drug abuse |
| gptkbp:dosage_form |
gptkb:patches
|
| gptkbp:duration |
up to 9 hours
|
| gptkbp:effective_date |
2006-04-01
|
| https://www.w3.org/2000/01/rdf-schema#label |
Daytrana
|
| gptkbp:indication |
gptkb:Attention_Deficit_Hyperactivity_Disorder_(ADHD)
|
| gptkbp:ingredients |
gptkb:Sannin
|
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Daytrana_Patch
|
| gptkbp:packaging |
single-use patches
|
| gptkbp:release_type |
controlled release
|
| gptkbp:requires |
prescription only
|
| gptkbp:route_of_administration |
transdermal
|
| gptkbp:side_effect |
anxiety
headache nausea decreased appetite insomnia |
| gptkbp:storage |
room temperature
|
| gptkbp:used_for |
treatment of ADHD
|
| gptkbp:weight |
225.31 g/mol
|
| gptkbp:bfsParent |
gptkb:Sannin
|
| gptkbp:bfsLayer |
5
|